Role of bacteria in the pathogenesis and progression of acute and chronic lung infection

R A Stockley

The lung presents a major interface between the external environment and the body. Although antigens, including viable bacteria, are inhaled on a regular basis, health is maintained and the organisms are excluded by a multitude of sophisticated and complex host defence mechanisms. These include the integrity of the bronchial epithelium and the efficiency of the mucociliary escalator which prevents bacterial adherence and penetration whilst at the same time facilitating their removal. In addition, the lung secretions contain various proteins including lysozyme and lactoferrin which prevent bacterial replication, as well as immunoglobulin A which prevents bacterial adhesion and scavenging phagocytic cells to destroy the bacteria that remain.

The relationship between the lung and bacteria can take on several abstract forms: (a) a transient relationship where the host remains intact, the bacterial load remains low, and the primary lung defences outlined above result in effective clearance; (b) acute infections where the bacterial load is higher, the local defences fail to cope, and bacterial numbers increase. At this point an acute inflammatory process occurs leading to the recruitment of the secondary lung defence systems including scavenging neutrophils. The patient becomes acutely unwell and the inflammatory response results in sterilisation of the bronchial tree and the infective process resolves; (c) colonisation: this usually occurs on the background of abnormal host defence. The process is low grade with a mild degree of inflammation and a balance is established between the local host defence mechanisms and bacterial replication to achieve a position of stability. This situation may be associated with recurrent acute exacerbations which are self-limiting and resolve; and (d) chronic infection: in this situation the bacterial load is sufficient to generate a marked inflammatory response that fails to clear the organism. It can become self-perpetuating and lead to the development of chronic progressive bronchial disease.1

The evidence for, and understanding of, these mechanisms is based on very carefully controlled animal experiments of acute and chronic infection together with transient observations in human subjects.2 The exact mechanisms involved remain to be clarified and much of our understanding of pathogenesis is based upon in vitro studies utilising pure cytokines and studying their effects. In vivo the situation may be much more complex, particularly since a “cocktail” of cytokines is released at the same time, some of which have diametrically opposed effects in vitro. Nevertheless, with this as a background it is possible to derive some concepts of the processes involved and some of the mediators that may be relevant.

Studies in man

The importance of the primary and secondary host defence in the relationship between the lung and bacteria can only be determined by indirect observations. Genetic disorders of mucociliary clearance (the major primary host defence) are known to be associated with the development and progression of chronic lung infection. In addition, systemic immune deficiency and disorders of neutrophil function (secondary host defence factors) are also associated with persistent recurrent infections. These defects clearly emphasise the importance of host defence. However, most patients with both acute and chronic infections do not appear to have any major defect of host defence that has yet been identified.34

ACUTE INFECTION/PNEUMONIA

This is a systemic illness in which the primary lung defence has been overcome by the inhaled bacteria. Secondary host defence mechanisms are activated with neutrophil infiltration and inflammation develops within the lung. These episodes are usually short lived and may be either fatal, self-limiting, or curtailed by the use of the appropriate antibiotic therapy. The process of acute infection should theoretically go through several stages. Once the inflammatory process has started there is likely to be an amplification stage which will result in either sufficient or insufficient recruitment of secondary host defences. If the response is sufficient the bacteria will be destroyed, the process will be switched off, and resolution will take place. On the other hand, if the amplification process is insufficient progressive illness may develop until antibiotic therapy
in conjunction with host defences results in bacterial destruction and subsequent resolution. These simple steps of initiation, amplification and resolution are outlined in fig 1.

Initiation
The initiation of the infective process occurs when sufficient bacteria are present in the lung and overcome the ability of local host defences to clear them. This may simply involve the inhalation of sufficient bacteria in the first instance, or may be potentiated by the release of various bacterial factors that interfere with host defences such as pyocyanin and hydroxyphenazine which significantly reduce mucociliary clearance, lipopolysaccharide which damages epithelium, or IgA proteases which damage secretory IgA and therefore may facilitate bacterial adherence to the epithelium.

At this point the inflammatory process is initiated. Evidence has shown that bacteria possess the ability to stimulate human bronchial epithelial cells to produce a variety of cytokines some of which may be pro-inflammatory. Of major importance is thought to be the chemoattractant interleukin 8 (IL-8) and tumour necrosis factor α (TNF-α). Epithelial IL-8 is a major neutrophil chemoattractant and, once released from the bronchial epithelium, it forms a diffusion gradient into the circulation attracting and activating nearby leukocytes. The process of neutrophil migration will be further enhanced by stimulation of endothelial cell adhesion molecules and, although some of these are constitutionally expressed on the endothelium, the release of pro-inflammatory cytokines such as TNF-α will increase the expression of these molecules and facilitate neutrophil adhesion.

Amplification
The recruitment of neutrophils to the airways may actually facilitate the amplification process. Activation of neutrophils has been shown to release both LTB4 and IL-8 which will add to the chemoattractant concentration in the airway and potentiate the diffusion gradient into the circulation. In addition, release of neutrophil elastase as the neutrophil becomes activated has also been shown to increase epithelial cell IL-8 production, again adding to the chemoattractant gradient.

Resolution
This whole process may be limited by a successful and adequate host response. Providing there is a sufficient degree of bacterial phagocytosis the process will become self-limiting. The mechanisms involved in switching off the host defence have been least studied. Simplistically the resolution process could take place if the bacterial load is reduced and this switches off the bacterial stimulus to the inflammatory phase (the contribution to IL-8 and TNF production). This in itself will reduce the drive to neutrophil recruitment. As fewer neutrophils are recruited and activated they will generate less IL-8 and LTB4 in their own right, as well as less neutrophil elastase to promote IL-8 production by the epithelial cell. This change in itself may be sufficient to switch off the inflammatory process but may be facilitated by the generation of anti-inflammatory cytokines.
At this point the acute phase response may also be important. Alpha-1-antitrypsin undergoes a 3–4-fold rise in serum concentrations during episodes of systemic inflammation. This, coupled with the increase in lung endothelial and epithelial permeability that occurs during infection, should result in a major increase in the diffusion of this proteinase inhibitor into the lung. The effect would be to limit the amount of active neutrophil elastase within the lung tissue and it may therefore serve as a mechanism for downregulating the inflammatory response being driven by the release of this enzyme. In addition, one of the other acute phase proteins, α1-antichymotrypsin, has been shown to be a major inhibitor of neutrophil chemotaxis.17 Again, the concentration of this protein rises dramatically during inflammation (several fold within 12 hours). The effect of this also could limit neutrophil traffic into the lung and thereby downgrade the inflammatory process.

Finally, during the process of resolution, apoptosis of the recruited neutrophils may be an important mechanism. How this takes place and its relationship to the initiation of the inflammatory process is difficult to discern. TNF-α has been shown to increase apoptosis in vitro14 and may therefore be important in the resolution of inflammation. However, as indicated above, the same cytokines may actually accentuate the inflammatory process by the stimulation of endothelial cell adhesion molecules. Furthermore, activation of neutrophils by endotoxin can prevent the effect of TNF on apoptosis.18 Thus, changes in the biochemical environment in the airway may affect the way the neutrophil responds to single or multiple factors. Similarly, studies have shown that IL-6 is also capable of promoting apoptosis19 and yet studies by Khair and colleagues have indicated that IL-6 is released at the same time as pro-inflammatory cytokines from bronchial epithelium exposed to endotoxin from Haemophilus influenzae.8 The rationalisation of these diverse properties and their relationship to the initiation and resolution of inflammation remains to be achieved.

COLONISATION

Colonisation represents a state between acute infection and complete resolution. It is generally associated with an identified breach in host defences and usually this is because of a defect in mucociliary clearance related to ciliary dysfunction, epithelial destruction, or abnormal mucus production. A failure of this important mechanism of clearance would, firstly, delay removal of bacteria from the lung and, secondly, provide a suitable culture medium for bacterial replication. Chronic colonisation therefore reflects a state in which bacterial replication keeps pace with the primary host defence clearance mechanisms.

There may be a low grade inflammatory process in patients with chronic bronchitis and emphysema in the stable clinical state. The patients may often have a significant bacterial load in their secretions (106 viable organisms/ml) plus a small number of recruited neutrophils and detectable plasma protein transudation into the secretions. Nevertheless, this represents virtually a symbiotic relationship. The bacteria isolated are usually those considered to be of low pathogenicity (Haemophilus influenzae, Moraxella catarrhalis, Haemophilus parainfluenzae) and may themselves facilitate this whole process by interfering with several mechanisms of host defence. For instance, bacterial products have been shown to interfere with neutrophil chemotactic responses16 and may therefore downregulate an important mechanism that would lead to sterilisation of the bronchial tree. In addition, bacteria have been shown to have a major effect on factors involved in mucociliary clearance. Cilia toxins have been shown to be produced by a variety of bacteria which colonise the airways in patients with chronic bronchial disease. In addition, bacteria can lead to excess mucus production in their own right13 and will therefore lead to chronic bronchitis. Bacterial products can cause epithelial damage4 which will facilitate bacterial adherence and again lead to a reduction in their clearance. Finally, pathogenic bacteria are known to produce IgA proteases7 which may therefore interfere with the ability of IgA to prevent bacterial adherence, again a process that would facilitate bacterial persistence in the airways.

It is possible that the process itself may be perpetuated by host immune defects. As indicated at the beginning of this article, major defects of immunity are associated with persistent and/or recurrent bacterial infections. However, most patients with chronic bronchial disease do not have a clearly identifiable immune defect. Nevertheless, there are studies which suggest that in some patients the immune response may be abnormal, resulting in the production of the wrong type of antibody that does not facilitate bacterial phagocytosis and clearance but rather acts as a blocking antibody, “protecting” the bacteria from normal clearance mechanisms.18

In addition, recent studies have suggested that the bacteria may be able to facilitate their survival by continually changing their antigenic nature to remain ahead of a host immune response.19 The importance of this mechanism in the persistence of bacteria in the airways of patients with bronchial disease and the initiation of acute exacerbations of chronic bronchitis is clearly worthy of further study.

CHRONIC INFECTION

Chronic bronchial infection appears to be associated with an overactive response of the immune system (which may indeed be inappropriate) and the perpetuation of the inflammatory response. Studies have shown that such patients often have increased circulating immunoglobulin levels and increased immunoglobulins in the secretions.8 The lung tissues contain increased numbers of immunoglobulin generating B cells,20 particularly the IgA1 and IgA2 subclasses.21 In addition, the T cell population is increased with the greatest increase
Role of bacteria in acute and chronic lung infection

Infect Immun

process (see fig 1). Alternatively, the response
not get switched on.

Haemophilus influenzae

or four months continuous therapy with amoxycillin given
beating of human respiratory cilia in vitro.

or high dose (HD) therapy (3 g amoxycillin twice daily),
antibiotic therapy (250 mg amoxycillin three times a day)
defences.

4 Bilton D, Leung AYT, Hill SL, Stockley RA. Defective lung
been treated with either two weeks of low dose (LD)
antibiotic therapy (250 mg amoxycillin three times a day)
response to Neutrophil elastase in respiratory epithelial lining fluid of
ff

orbital or by the inhaled route. Published with permission from Stockley.22

being in the Ti suppressor subset.20 The lung
tissues and airways contain large numbers of
neutrophils as part of the inflammatory re-
sponse, but in this situation neutrophil re-
cruitment and activation is persistent and does
not get switched off unless successful antibiotic intervention occurs, and even then the response
may be short lived.22

The processes involved can only be alluded to. The inhalation of large numbers of bacteria
would initiate the inflammatory process. The
amplification stage should take place normally
but the response itself may be insufficient to
clear bacteria which continues the amplification
process (see fig 1). Alternatively, the response
may be excessive which in itself may be counterproductive, destructive, and facilitate bacterial survival, thereby perpetuating the pro-
cess. In this respect the role of the neutrophil has
been implicated as a major factor.1 Neutro-
phil recruitment and activation results in the
release of a variety of tissue damaging sub-
cstances including neutrophil proteinases and
oxidants. These may interfere with host de-
fences in various ways including reduction of
mucociliary clearance, excess mucus produc-
tion, mucus gland hyperplasia, bronchial epithe-
lial damage (facilitating bacterial ad-
herence), damage to immunoglobulins (pre-
venting opsonisation), and even destruction of
phagocytic receptors on the neutrophil itself
(reducing opsonophagocytosis). This sequence
of events has led to the concept of neutrophil
mediated progression of chronic bronchial dis-
ease and persistence of chronic infection.1 As
intimated above, the process can often be re-
versed by the use of appropriate antibiotics.
However, such responses are usually short lived
and patients may require long term antibiotic
therapy in order to downregulate the in-
flammatory process and prevent persistent
bronchial disease. In some instances this pro-
cess may be permanently reversed, such that
withdrawal of antibiotic therapy after a period
of time may not be associated with an im-
mediate return to the chronic infective state
(fig 2).

In conclusion, bacteria play a role in initiating
the processes involved in both acute and
chronic lung infection. The former are usually
short lived episodes which generally result in
resolution and the return to a state of health.
In the latter case the infective process, although
relatively confined to the lung, may persist and
be associated with processes that perpetuate
and in most severe cases be related to pro-
gression of the chronic lung disease.

1 Stockley RA. Bronchiectasis: new therapeutic approaches
2 Stockley RA, Hill SL, Morrison HM. Effective antibiotic
treatment on sputum elastase in bronchiectatic patients
3 Stanley PJ, Korbo G, Cole PJ. Serum IgG subclasses in chronic
and recurrent respiratory infection. Clin Exp Immunol
4 Bilton D, Leung AYT, Hill SL, Stockley RA. Defective lung
phenazine produced by Pseudomonas aerugi
osa inhibit the beating of human respiratory cilia in vitro. J Clin Invest
6 Wilson R, Sykes D, Rutman A, et al. The effect of Haemo-
philus influenzae lipopolysaccharide on human respiratory
7 Kilian M, Mestecky J, Kullberg R, et al. IgA proteases from
Haemophilus influenzae, Streptococcus pneumoniae, Neisseria
meningitidis and Streptococcus sanguis: comparative im-
8 Khar OA, Devaka JL, Abdelaziz MM, et al. Effect of
Haemophilus influenzae endotoxin on the synthesis of IL-
6, IL-8, TNF-α and expression of ICAM1 in cultured
human bronchial epithelial cells. Eur Respir J 1997;
2109–16
9 Wardlaw A. Leukocyte adhesion to endothelium. Clin Exp
B4 – a potent chemokinetic and aggregating substance
11 Takehashi GW, Andrews DF, Lilly MB, et al. Effect of
granulocyte-macrophage colony-stimulating factor and
interleukin-3 on interleukin-8 production by human
12 Nakamura H, Yoshimura K, McElvany NG, Crystal RG.
Neutrophil elastase in respiratory epithelial lining fluid of
dividuals with cystic fibrosis induces interleukin-8 gene
expression in the human bronchial epithelial cell line. J
of neutrophil chemotaxis by inhibitors of cathespin G and
14 Hachiyu O, Takeda Y, Miyata H, Watanabe H, Yamashita
T, Sendo F. Inhibition by bacterial lipopolysaccharide of
spontaneous and TNFα-induced human neutrophil
15 Afford SC, Pongracz J, Stockley RA, et al. The induction by
human Interleukin-6 of apoptosis in the promonocytic
macrophage cell line U937 and human neutrophils. J Clin
16 Cundell DR, Taylor GW, Kanthakumar K, et al. Inhibition of
human neutrophil migration in vitro by low-molecular-
weight products of non typeable Haemophilus influenzae.
17 Li JD, Dohrmann AF, Gallup M, et al. Transcriptional ac-
tivation of mucin by Pseudomonas aerugi
osa lipopoly-

Figure 2 Effect of antibiotics on relapse from chronic infectious bronchiectasis showing the number of days from cessation of effective antibiotic therapy to the chronic infective state. Each point indicates the results of an individual patient. The results are for patients who have been treated with either two weeks of low dose (LD) antibiotic therapy (250 mg amoxycillin three times a day) or high dose (HD) therapy (3 g amoxycillin twice daily), or for months continuous therapy with amoxycillin given in effective doses orally or by the inhaled route. Published with permission from Stockley.22

Downloaded from http://thorax.bmj.com/ on June 27, 2017 - Published by group.bmj.com
Lung infections. 1. Role of bacteria in the pathogenesis and progression of acute and chronic lung infection.

R A Stockley

doi: 10.1136/thx.53.1.58

Updated information and services can be found at: http://thorax.bmj.com/content/53/1/58.citation

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Inflammation (1020)
- Lung infection (97)
- TB and other respiratory infections (1273)
- Pneumonia (infectious disease) (579)
- Pneumonia (respiratory medicine) (562)
- Chemotherapy (183)
- Drugs: infectious diseases (968)
- Clinical genetics (27)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/